Clinical trials: aldesleukin
Chronic Graft-versus-host-disease
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
This research study is evaluating a combination of a therapy called Extra-corporeal Photopheresis (ECP) with a drug called Interleukin-2 (IL-2) as a possible treatment for chronic graft-versus-host-disease (GVHD) following…
- Trial name
- NCT02340676
- Testing
- Extracorporeal Photopheresis (ECP), Interleukin-2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Kita-kyushu Lung Cancer Antigen 1, Human
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Background: Researchers have found a new way to treat cancer using T cell therapy. The therapy used in this study is T Cell Receptor (TCR) Gene Therapy Targeting Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1), a cancer germline…
- Trial name
- NCT05035407
- Testing
- IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
The main goal of the research study is to determine whether treating renal cell cancer patients with the study drug, hydroxychloroquine, along with IL-2, a standard treatment of kidney cancer that has spread to other parts of the…
- Trial name
- NCT01550367
- Testing
- Hydroxychloroquine, IL-2
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Leonard Appleman
Metastatic Melanoma, Skin Cancer
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Background: Some cancer treatments collect a patient s own blood cells to use as specialized cancer-fighting cells. Collected white blood cells known as PBL (peripheral blood lymphocytes) can use to isolate special cells that can…
- Trial name
- NCT01495572
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
Background: Melanoma antigen recognized by T cells (MART-1) is a gene that is present in melanoma cells. This study tests an experimental treatment that uses the patient's own lymphocytes (type of white blood cell), which are…
- Trial name
- NCT00706992
- Testing
- ALVAC-MART-1 vaccine, MART-1:26-35(27L) peptide vaccine, Aldesleukin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infection
Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)
This study will examine whether interleukin-2 (IL-2) plus antiretroviral therapy (ART) slows HIV disease progression in patients with low CD4+ T cell counts compared with patients taking ART alone.
- Trial name
- SILCAAT (NCT00013611)
- Testing
- Proleukin
- Where
- United States
- Volunteers
- 1,695 people
- Sponsor
- University of Minnesota
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
This phase I trial studies the side effects and best dose of aldesleukin when given together with pembrolizumab in treating patients with kidney cancer that has spread to other parts of the body.
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- NCT03260504
- Testing
- Aldesleukin, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
This phase I/II trial studies the side effects and best dose of donor natural killer cells when given together with donor stem cell transplant and to see how well they work in treating patients with myeloid malignancies that are…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT01823198
- Testing
- Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
The purpose of this phase 2 study is to find the best way to give this new experimental regimen and determine if it can treat metastatic melanoma in humans.
- Trial name
- F5 (NCT00910650)
- Testing
- F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative conditioning chemotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center